Switch to dark mode to head towards a more sustainable world together. More info GSK is committed to disclosing the payments we make as we work together with healthcare professionals For patients to benefit from new medical innovations HCPs need to access and understand the latest available data and clinical use of the product Feedback from HCPs shows that they prefer to learn about new data and clinical experience through peer-to-peer programmes with global expert practitioners who have direct experience with our medicines To help HCPs share new data on our products and understand their clinical use This policy is limited to select products in certain countries around the world and controls and training are in place including measures to track appropriate payment and use of external speakers we will report individual-level payments made each year to HCPs for attending educational meetings and for the provision of services such as speaking at events or attending advisory boards Where individual level disclosure is not legally permitted we will continue to report aggregate payments Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials administer the investigational medicine or vaccine to patients All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment We have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research As part of our global corporate commitment to the highest standards of transparency and ethics in our business practices GSK has decided to disclose payments or transfers of value to healthcare professionals for services provided to GSK in accordance with the terms of contracts with such third parties Such services include activities such as speaking at a conference providing advice as a member of an expert advisory board or as a consultant as well as travel and accommodation expenses associated with those services GSK made payments totalling DZD 4,297,372.41 – and £ 25,278.66 to a total of 22 healthcare professionals with an average payment of DZD 195,335.11 – and £ 1,149.03 /HCP GSK made payments totalling DZD 9,973,82.81/£ 5,866.96 to a total of 6 healthcare professionals with an average payment of DZD 166,230.47/£ 977.83 per HCP salim.x.aitbelkacem@gsk.com GSK made payments totalling ARS 150,229,059.59 – £ 476,917.65 to a total of 208 healthcare professionals with an average payment of ARS 722,255.09 – £ 2,292.87 / HCP GSK made payments totalling ARS 76,503,570.18/£ 437,163.26 to a total of 185 healthcare professionals with an average payment of ARS 413,532.81/£ 2,363.04 per HCP GSK made payments totalling ARS 22,505,278.81 to a total of 143 healthcare professionals Please contact Piera Basile – Senior Communications and Government Affairs Manager piera.m.basile@gsk.com GSK has pledged to disclose the transfers of value that we make to HCPs and HCOs in connection with prescription medicines on an individual named basis (aggregate by exception only) This includes sponsorship for travel and registration fees to attend medical congresses fees for speaker arrangements or for chairing meetings and grants to HCOs Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number The links below will take you to our disclosures for Austria in line with the EFPIA code and to a note on the methodology used to set out the data in the report +43 664 8270120 barbara.b.masser-mayerl@gsk.com GSK made payments totalling 15,555 BHD (32,665 £) to a total of 25 healthcare professionals with an average payment of 622 BHD (1,307 £) /HCP GSK made payments totalling BHD 8,881/£ 19,006 to a total of 21 healthcare professionals with an average payment of BHD 423/£ 905 per HCP 4,725 to a total number of 14 HCPs with an average payment of BHD 338 per HCP +971 564014498 averyan.g.vasylyev@gsk.com The links below will take you to our disclosures for Belgium in line with the EFPIA code and pharma.be code Consult the register The significant presence of GSK Vaccines in Belgium where the global centre for R&D (research & development) as well as the manufacturing site of vaccines explain why some local collaborations with Healthcare Professionals and Organisations have an international dimension +32 478 27 26 41 Elisabeth.e.vandamme@gsk.com WW.CEEurope-media@gsk.com GSK made payments totalling R$ 10.307.475 – £ 1.598.059 to a total of 3.688 healthcare professionals with an average payment of R$ 2.795 – and £ 433 /HCP GSK made payments totalling R$ 3,754,422/£ 528,792 to a total of 2,614 healthcare professionals with an average payment of R$ 1,436/£ 202 per HCP to a total number of 142 HCPs with an average payment of R$ 7.148/HCP ingrid.a.santos@gsk.com The links below will take you to our disclosures for Bulgaria in line with the EFPIA code GSK made payments totalling CLP 286,755,757.50 – 298,728.71 to a total of 144 healthcare professionals with an average payment of CLP GSK made payments totalling $89,039,097/£ 87,723.25 to a total of 55 healthcare professionals with an average payment of $ 1,413,319/£ 1,392.43 per HCP we have paid CLP $39,033,792 to a total number of 44 HCPs with an average payment of CLP $756,368./HCP Please contact Mariella Francesca Parodi Soza Communications & Government Affairs Head +56 954023957 mariella.x.parodi@gsk.com GSK made payments totalling COP$ 979,901,774.00/ £201,046.73 to a total of 88 healthcare professionals with an average payment of COP$ 11,135,247.73 / £ 2,284.62 /HCP GSK made payments totalling COP$ 830,321,971/£ 166,731.32 to a total of 69 healthcare professionals with an average payment of COP$ 12,033,652/£ 2,416 per HCP we have paid COP 160.733.320 to a total number of 30 HCPs with an average payment of COP 5.357.777/HCP Communications and Government Affairs Head +57 3243457682 juan.f.garcia@gsk.com GSK made payments totalling $61,139.89 – £42,165.44 to a total of 37 healthcare professionals with an average payment of $1,652.43 – £1,139.61 /HCP GSK made payments totalling $10,813.10/£7,457.31 to a total of 14 healthcare professionals with an average payment of $ 772.36/£ 532.67 per HCP Communications and Government Affairs Manager sabrina.x.mujica@gsk.com The links below will take you to our disclosures for Croatia in line with the EFPIA code The links below will take you to our disclosures for Cyprus in line with the EFPIA code PDF (123KB) PDF (237KB) The links below will take you to our disclosures for Czech Republic in line with the EFPIA code EFPIA has assessed the Danish legislation on disclosure (decree number L94/2013-14) to meet the requirements for transparency and has exempted Denmark from implementing the EFPIA Disclosure Code given the disclosures are already disclosed through the Danish Medicines Agency / Laegemiddelstyrelsen. Legislation in Denmark requires HCPs to self-disclose: Our disclosures in Denmark via Danish Medicines Agency / Laegemiddelstyrelsen include all transfers of value made by GSK to individual HCPs Any payments to HCOs and hospitals in Denmark are disclosed on the Grants & Donations section on GSKPro and in a yearly report on the homepage of ENLI (The Ethical Comittee for the Pharmaceutical Industry) helle.a.hellberg@gsk.com GSK made payments totalling $67,664.62 – £46,665.26 to a total of 40 healthcare professionals with an average payment of $1,691.62 – £1,166.63 /HCP GSK made payments totalling $6,517.13/£4,494.57 to a total of 11 healthcare professionals with an average payment of $592.47/£408.60 per HCP sabrina.x.mujica@gsk.com GSK made payments totalling USD 18,955.33 – and £ 13,395.22 to a total of healthcare 20 professionals with an average payment of USD 3,145.55 – and £ 2,491.92 /HCP GSK made payments totaling USD 6,746.80/£5,475.26 to a total of 10 healthcare professionals with an average payment of USD 674.68/£547.52 per HCP GSK made payments totalling [EGP 3,174,332 – and £ 144,282.80] to a total of [152] healthcare professionals with an average payment of [EGP 20,884 – and £ 949.26] /HCP GSK made payments totalling EGP 760,854/£ 34,584.27 to a total of 20 healthcare professionals with an average payment of EGP 38,043/£ 1,729.21 per HCP Communications and Government Affairs Head Egypt omar.s.shoukry@gsk.com GSK made payments totalling $33,090.89 – £22,821.30 to a total of 22 healthcare professionals with an average payment of $1,504.13 – £1,037.33 /HCP GSK made payments totalling $2,627.43/£1,812.02 to a total of 6 healthcare professionals with an average payment of $437.91/£302 per HCP The links below will take you to our disclosures for Estonia in line with the EFPIA code The links below will take you to our disclosures for Finland in line with the EFPIA code +358 50 4200401 anna.v.dammert@gsk.com The links below will take you to our disclosures for France in line with the EFPIA code +33 139178538 victoria.v.morel@gsk.com The links below will take you to our disclosures for Germany in line with the EFPIA code pia.x.clary@gsk.com The links below will take you to our disclosures for Greece in line with the EFPIA code Government Affairs & Market Access Director +30 210 6882170 vasilia.x.papagiannopoulou@gsk.com GSK made payments totalling $36,670.33 – £25,289.88 to a total of 25 healthcare professionals with an average payment of $1,466.81 – £1,011.60 /HCP GSK made payments totalling $6,290.49/£4,338.27 to a total 11 healthcare professionals with an average payment of $571.86/£394.39 per HCP The links below will take you to our disclosures for Hungary in line with the EFPIA code GSK made payments totalling $49,208.50 – £33,936.90 to a total of 26 healthcare professionals with an average payment of $1,892.63 – £1,305.27 /HCP GSK made payments totalling $2,392.28/£1,649.85 to a total 7 healthcare professionals with an average payment of $341.75/£235.70 per HCP GSK made payments totalling 38,714 KWD (99,495 £) to a total of 84 healthcare professionals with an average payment of 461 KWD (1,184 £) /HCP GSK made payments totalling KWD 30,201/£ 79,428 to a total of 50 healthcare professionals with an average payment of KWD 604/£ 1,589 per HCP we have paid 11,540 KWD to a total number of 30 HCPs with an average payment of 385 KWD per HCP The link below will take you to our disclosures for Ireland in line with the EFPIA code and Irish Pharmaceutical Healthcare Association (IPHA) code http://www.transferofvalue.ie/ Head of Communications and Government Affairs +353 868151467 marguerite.o.o'loughlin@gsk.com GSK made payments totalling Rp 7,552,044,439,- or £394,177 to a total of 1226 healthcare professionals with an average payment of Rp 6,159,906,- or £322/HCP GSK made payments totalling Rp 1,657,844,430/£86,531 to a total of 236 healthcare professionals with an average payment of Rp 7,024,765/£367 per HCP reswita.x.derygisriani@gsk.com The links below will take you to our disclosures for Israel in line with the EFPIA code margalit.k.keren@gsk.com The links below will take you to our disclosures for Italy in line with the EFPIA code A specific focus on 2023 VIIV Healthcare TOV in favour of Italian HCPs and HCOs in Italy is available on ViiV Healthcare Italy maa5798@gsk.com GSK made payments totalling $27,086.83 – £18,680.57 to a total of 19 healthcare professionals with an average payment of $1,425.62 – £983.19 /HCP GSK made payments totalling $1,376.52/£949.32 to a total of 2 healthcare professionals with an average payment of $688.26/£474.66 per HCP Please find latest local disclosure report combining data from different companies published by Latvian Health Inspectorate. A distributor SIA TAMRO (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Latvia Transfers of Value made to HCPs / HCOs are reported separately by SIA TAMRO and should be considered together with transfers of value made by GSK directly The links below will take you to our previous year’s disclosures for Latvia in line with the EFPIA code published on the Latvian Health Inspectorate website since 2021 New local disclosure report will be published on State Medicines Control Agency Lithuania website by August 1 A distributor UAB „Tamro“ (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Lithuania Transfers of Value made to HCPs / HCOs are reported separately by UAB TAMRO and should be considered together with transfers of value made by GSK directly transfers of value made by GSK to HCOs reported on the State Medicines Control Agency should be considered together with transfers of value made by GSK that are not reportable to the State Medicines Control Agency The links below will take you to our disclosures for Lithuania in line with the EFPIA code and IFPA The links below will take you to our disclosures for Luxembourg in line with the EFPIA code and IML code Code of ethics | IML elisabeth.e.vandamme@gsk.com GSK made payments totalling RM 359,569.99 (£65,614.96) to a total of 149 healthcare professionals with an average payment of RM 2,413.22 (£440.37)/HCP GSK made payments totalling RM 164,972.05/£ 30,104.39 to a total of 88 healthcare professionals with an average payment of RM 1,874.68/£342.10 per HCP we have paid RM 57,000 to a total number of 34 HCPs Government Affairs & Strategic Customer Solutions my.corporatecommunications@gsk.com The links below will take you to our disclosures for Malta in line with the EFPIA code GSK made payments totalling MXN $8,544,346 - £348,749 to a total of 156 Healthcare Professionals with an average of payment of MXN $54,771 - £2,236 /HCP GSK made payments totalling MXN 9,447,264/£ 337,402 to a total of 170 healthcare professionals with an average payment of MXN 55,572/£ 1,984 per HCP we have paid $7,079,128 MXN to a total number of 139 HCPs with an average payment of $50,929 MXN /HCP Communications and Government Affairs Lead emma.x.prian@gsk.com 823,474.53 – and £ 66,409.24] to a total of [66] healthcare professionals with an average payment of [MAD GSK made payments totalling MAD 595,204.68/£ 48,000.38 to a total of 21 healthcare professionals with an average payment of MAD 28,334.08/£ 2,285.73 per HCP Communication & Government Affairs Lead omar.a.el-mrabet@gsk.com The links below will take you to our disclosures for the Netherlands in line with the EFPIA code and Code for Pharmaceutical Advertising (the CGR) Transfers of value for research and development are not part of the Transparency Register and is therefore listed separately for GSK Netherlands https://www.transparantieregister.nl/homepage/zoek-uw-zorgaanbieder +31 (0) 6 13 51 11 88 The links below will take you to our disclosures for North Macedonia in line with the EFPIA code The links below will take you to our disclosures for Norway in line with the EFPIA code Head of Government Affairs and Communication +47 227 02 000 no.firmapost@gsk.com GSK made payments totalling 8,654 OMR (17,740 £) to a total of 29 healthcare professionals with an average payment of 298 OMR (612 £) /HCP GSK made payments totalling OMR 16,774/£ 35,225 to a total of 19 healthcare professionals with an average payment of OMR 883/£ 1,854 per HCP we have paid 6,266 OMR to a total number of 8 HCPs with an average payment of 783 OMR per HCP GSK made payments totalling PKR 8,762,179 – and £35,121 to a total of 102 healthcare professionals with an average payment of PKR 85,904 – and £344.3 /HCP GSK made payments totalling PKR 1,975,465/£ 8,979.4 to a total of 15 healthcare professionals with an average payment of PKR 131,697.7/£ 598.63 per HCP Director Corporate Governance Affairs & Administration sumera.x.naveed@gsk.com GSK made payments totalling $47,859.20 – £33,006.34 to a total of 28 healthcare professionals with an average payment of $1,709.26 – £1,178.80 /HCP GSK made payments totalling $6,781.90/£4,677.17 to a total of 9 healthcare professionals with an average payment of $753.5/£519.69 per HCP GSK made payments totalling PEN 27,700.97 – and £8,969.08 to a total of 9 healthcare professionals with an average payment of PEN 1,846.73 – and £597.94 /HCP GSK made payments totalling PEN 34,078.27/£7,486.1 to a total of 11 healthcare professionals with an average payment of PEN 2,004.60/£440.36 per HCP GSK made payments totalling ₱ 17,346,982 / £ 266,877 to a total of 694 healthcare professionals with an average payment of ₱ 24,996 / £ 385 per HCP GSK made payments totalling ₱ 5,169,060/£ 79,560 to a total of 117 healthcare professionals with an average payment of ₱ 44,180/£ 680 per HCP Disclaimer: This is a demonstration of GSK's transparency commitments as a global organization based on its independent selection of in scope activities the values herein disclosed may vary from GSK Philippines Inc.'s declaration in compliance with the local legal disclosure requirements no data privacy rights of any HCP has been breached by the foregoing disclosure richard.b.arboleda@gsk.com The links below will take you to our disclosures for Poland in line with the EFPIA code Please contact Małgorzata Stolarczyk-Zdrojkowska +48 573 20 50 50 malgorzata.x.stolarczyk-zdrojkowska@gsk.com Our disclosures in Portugal via Infarmed include all transfers of value made by GSK to individual HCPs as well as HCOs as required under Portuguese national law +351 918699965 joao.x.duarte@gsk.com GSK made payments totalling 95,628 QAR (21,038 £) to a total of 23 healthcare professionals with an average payment of 4,158 QAR (915 £) /HCP GSK made payments totalling QAR 50,721/£ 11,060 to a total of 12 healthcare professionals with an average payment of QAR 4,189/£ 922 per HCP we have paid 68,267 QAR to a total number of 20 HCPs with an average payment of 3,413 QAR per HCP +971 564014498 averyan.g.vasylyev@gsk.com The links below will take you to our disclosures for Romania in line with the EFPIA code and the local legislation requirements A distributor EL PHARMA ROMANIA SRL (“Phoenix”) is involved in the promotion of medicines on behalf of GSK in Romania. Transfers of Value made to HCPs / HCOs are reported separately by the local Phoenix entity on Sponsorizari – Medicamente de uz uman – ANMDMR (as per law no 95/2006 and OMS 194/2015) and should be considered together with transfers of value made by GSK directly The links below will take you to our disclosures for Russia in line with the EFPIA code olga.x.korshakova@gsk.com GSK made payments totalling [SAR 5,019,994 – and GBP 1,024,488] to a total of [3166] healthcare professionals with an average payment of [SAR GSK made payments totalling SAR 3,167,722/£ 621,121 to a total of 1663 healthcare professionals with an average payment of SAR 1,905/£ 374 per HCP we have paid 2,194,725 SAR (623,990 USD) to 1694 HCPs with an average payment of 1,296 SAR (368 USD) per HCP sattam.t.alghodyyr@gsk.com The links below will take you to our disclosures for Serbia and Montenegro in line with the EFPIA code The links below will take you to our disclosures for Slovakia in line with the EFPIA code The links below will take you to our disclosures for Slovenia in line with the EFPIA code The links below will take you to our disclosures for Spain in line with the EFPIA code tca.dptocomunicacion@gsk.com The links below will take you to our disclosures for Sweden in line with the EFPIA code External Affairs & Market Access Director maria.b.ericson@gsk.com The links below will take you to our disclosures for Switzerland in line with the EFPIA code Corporate Affairs Director or Manuel Mosimann +41 (0) 79 292 56 91 +41 (0) 79 948 43 51 urs.b.kientsch@gsk.com manuel.x.mosimann@gsk.com GSK made payments totalling 31,193,767.47 THB or 693,194.83 £ to a total of 1,723 healthcare professionals with an average payment of 18,104.33 THB or 402.32 £ /HCP GSK made payments totalling THB 13,037,306/£289,717.92 to a total of 816 healthcare professionals with an average payment of THB 15,977/£355 per HCP we have paid 102,639 GBP to a total number of 654 HCPs* with an average payment of 157 GBP/HCP supattra.x.harncharoen@gsk.com GSK made payments totalling $67,063.42 – £46,250.63 to a total of 33 healthcare professionals with an average payment of $2,032.22 – £1,401.53 /HCP GSK made payments totalling $1,290/£ 889.66 to a total of 1 healthcare professionals with an average payment of $1,290/£889.66 per HCP GSK made payments totalling ₺45,169,759.14 – £1,090,495.93 to a total of 6,885 healthcare professionals with an average payment of ₺6,560.60 – £158.39 /HCP GSK made payments totaling ₺15,970,658.48 - £539,002.99 to a total of 3,831 healthcare professionals with an average payment of ₺4,168.80 - £140.70 / HCP Communications & Patient Relations Manager zeynep.z.birgul@gsk.com The links below will take you to our disclosures for Ukraine in line with the EFPIA code and APRaD +380 50 415 52 40 olga.s.vorobiova@gsk.com Our payments to HCPs include the provision of services such as giving a lecture attending/ supporting educational meetings providing advice as a member of an Advisory Board or as a Consultant GSK’s voluntary decision to publish our payments to HCPs is part of our commitment to greater transparency and high ethical standards in our business practices GSK made payments totalling 1,956,818 AED (410,932 £) to a total of 327 healthcare professionals with an average payment of 5,984 AED (1,257 £) /HCP GSK made payments totalling AED 780,835/£171,784 to a total of 109 healthcare professionals with an average payment of AED 7,164/£1,576 per HCP we have paid 329,937 AED to a total number of 62 HCPs with an average payment of 5,322 AED per HCP The links below will take you to our disclosures for United Kingdom in line with the EFPIA code uk.media@gsk.com GSK made payments totalling [10,181,293,808.96 ₫ – and £ 305,048.35] to a total of 1459 healthcare professionals with an average payment of [6,978,268.55 ₫ – and £ 209.08] /HCP GSK made payments totalling ₫ 4,165,080,739.05/£ 124,792.69 to a total of 616 healthcare professionals with an average payment of ₫ 6,761,494.71/£ 202.59 per HCP Disclaimer: Travel and accommodation expenses are paid to GSK’s event organiser and not to HCPs phuong.n.pham@gsk.com Diem Nguyen Nhu Phuc: diem.p.nguyen-nhu@gsk.com This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector. © 2001-2024 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG Hermann and Margrit Rupf were close friends with Paul and Lily Klee and after 1913 they regularly acquired works from Klee Considered by the Nazis a “degenerate artist,” Klee moved back to Bern after the closure of the Bauhaus Dessau in the early 1930s the Rupfs met Vasily Kandinsky and his wife and the Rupfs remained close with Nina Kandinsky even after her husband’s death in 1944 Sixteen of his works (six of which can be seen in this exhibition) reached the Collection of Hermann and Margrit Rupf Kandinsky’s works in the show date from 1916 to 1940 and encompass his oeuvre from his temporary return to Russia until his later works in Paris The selection in this gallery highlights the fact that the Rupf Collection was never supposed to be viewed as complete but as an ensemble which should continue to evolve through time and remain a fascinating continuation of the Rupfs’ original collection mainly through the undeniable preference of the Collection’s acquisition policy for constructivist and conceptual art An exhibition dedicated to Paul Klee(Münchenbuchsee 1940) is on view at the Beyeler Museum in Basel Klee finally chose the latter and became an exponent ofabstractionism: “I am abstract with some memory,” the artist himself stated in one of his writings.The Basel exhibition hosts about a hundred works by the Swiss artist The exhibition brings together valuable loans from numerous institutions and private collections in Europe and elsewhere including MOMA - Museum of Modern Art in New York (“Fire in the Evening,” 1929) the National Museum of Modern Art in Tokyo ("Tree in Bloom," 1925) and prestigious private collections The exhibition will also feature works that are usually little exhibited and will allow people to discover Klee in a new light is the most represented artist in the Beyeler Collection supported Paul Klee’s work in multiple ways The collector’s passion focused primarily on Klee’s late work which he particularly appreciated for “its chromatic quality and expressive force which took his artistic production to the highest levels of simplification and abstraction include the 1931 “Rising Star” and the 1937 "Signs in Yellow." to trips to Egypt and Italy in the late 1920s and finally to the opulent mature work of the 1930s Blühendes - “Blooming” (1934; oil on canvas Look out for your first newsletter in your inbox soon We help you navigate a myriad of possibilities Sign up for our newsletter for the best of the city By entering your email address you agree to our Terms of Use and Privacy Policy and consent to receive emails from Time Out about news, events, offers and partner promotions. Switzerland facebook twitter About us Contact us As a colleague and a good friend of the famous Wassily Kandinsky who also taught at the famous art school Bauhaus Klee’s work is often referred as purely abstract It is said that it reflects a deep and almost childlike perspective of his mood His sheer pictorial language and pioneering Cubism examples at the Bauhaus have been The 20th century Modernism or Expressionism may be too vague to describe Klee’s work even though he has often been related to the many art movements such as Cubism and Expressionism In an attempt to master his color and overall texture technique early on he was associated with the artistic group Der Blaue Reiter (The Blue Rider) Klee’s artwork also incorporates a touch of sarcasm he was also fascinated with children’s art and its sheer simplicity His dream-like paintings were correlated with Surrealism Klee’s work is regarded as simplistic and abstract and can also be seen as humorous his work conveys a playful sense of absurdity since he was inspired by the basic techniques used by children That can be seen in his famous “Twittering Machine” (1922) It is one of better-known works of Klee and is frequently visited by many in the New York Museum of Modern Art (MoMA) Paul Klee was an extremely dedicated painter With more than 10,000 artworks under his belt Klee has cemented his reputation even in the early 20th century Klee abandoned his detailed expressionistic paintings and began to paint thicker surface He simplified his works to the point of depicting obvious childlike objects with bolder forms his highly musical upbringing can be definitely seen in his works Klee has been a big fan of classical music he took drawing and painting lessons as his primary conduct His artistic subjects and objects were directly influenced by music Klee never failed to depict his specific emotion or temperament who was a highly acclaimed architect and the founder of Bauhaus in Weimar The school of architecture and industrial design was also used for teaching the arts Nearly half of Klee’s almost 10,000 works were created when he was teaching at the Bauhaus many of them were destroyed and negatively exhibited at the Entartete Kunst (Degenerate Art) exhibitions by the Gestapo in 1933 The Nazis condemned modern art as an abomination and many artists at the time suffered great losses as thousands of modernist works were incinerated and destroyed a wasting disease which greatly diminished Klee’s health and breathing difficulties because of the scleroderma The once lively and humorous textures were turned into more darker colors and simpler objects which greatly represented the suffering he was going through on 29th June 1940 and was buried at Schosshaldenfriedhof Klee’s artwork was perhaps considered too revolutionary too outlandish for the Swiss authorities to grasp the Swiss accepted his posthumous request and granted him citizenship An estimated opus of about 9,000 works of art Klee has cemented his place among the greatest Expressionists that have ever lived Read another story from us: Basquiat: the Neo-Expressionist painter known for his primitive style & friendship with Andy Warhol For my dwelling place is as much among the dead Slightly closer to the heart of creation than usual Brad Smithfield is one of the authors writing for The Vintage News Join 1000s of subscribers and receive the best Vintage News in your mailbox for FREE